Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

<div>Use of anticoagulant agents in patients with nonvalvular AF according to the CHA<sub>2</sub>DS<sub>2</sub>-VASc score. DOACs: direct oral anticoagulant agents; LMWH: low molecular weight heparin; VKA: vitamin K antagonist.</div>

International Journal of Vascular Medicine

fig1

Figure 1

Figure 1: Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study 

Figure 1 | Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study 